Literature DB >> 4851751

Effects of haemoperfusion through charcoal or XAD-2 resin on an animal model of fulminant liver failure.

M J Weston, B G Gazzard, B H Buxton, J Winch, A L Machado, H Flax, R Williams.   

Abstract

In a group of dogs in whom fulminant liver failure had been induced, perfusion of blood through activated charcoal resulted in a significantly longer survival than that of a similar group of dogs whose blood was not so treated. An otherwise progressive rise in blood ammonia concentration was halted in the treatment group. In another group of dogs with fulminant liver failure perfusion of blood through the resin Amberlite XAD-2 was associated with a fall in the serum bilirubin concentration and complete clearance from the blood of (14)C-labelled sodium glycocholate. Survival in this group of animals was not significantly prolonged. This was due at least in part to the occurrence of haemorrhage due to thrombocytopenia. Platelets adhere to the resin but do not adhere to the same degree to charcoal coated with a thin layer of polymer.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4851751      PMCID: PMC1412998          DOI: 10.1136/gut.15.6.482

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

Review 1.  HEPATIC COMA; TREATMENT EMPHASIZING MERIT OF PERITONEAL DIALYSIS.

Authors:  L I NIENHUIS; E I MULMED; J W KELLEY
Journal:  Am J Surg       Date:  1963-12       Impact factor: 2.565

2.  TREATMENT OF SEVERE BARBITURATE POISONING.

Authors:  H YATZIDIS; D OREOPOULOS; D TRIANTAPHYLLIDIS; S VOUDICLARI; N TSAPARAS; C GAVRAS; A STAVROULAKI
Journal:  Lancet       Date:  1965-07-31       Impact factor: 79.321

3.  Ammonia intoxication treated by hemodialysis.

Authors:  J E KILEY; J C PENDER; H F WELCH; C S WELCH
Journal:  N Engl J Med       Date:  1958-12-11       Impact factor: 91.245

4.  Peritoneal dialysis in liver coma.

Authors:  R C JONES; L D STRADER; W C BERRY
Journal:  U S Armed Forces Med J       Date:  1959-08

5.  Hepatic coma following ischemia of the liver.

Authors:  A M RAPPAPORT; M H MACDONALD; Z J BOROWY
Journal:  Surg Gynecol Obstet       Date:  1953-12

6.  Blood ammonia and electrolytes in hepatic coma.

Authors:  R SCHWARTZ; G B PHILLIPS; G J GABUZDA; C S DIVIDSON
Journal:  J Lab Clin Med       Date:  1953-10

7.  Toward an artificial liver: in vitro removal of unbound and protein-bound plasma compounds related to hepatic failure.

Authors:  R A Willson; K H Webster; A F Hofmann; W H Summerskill
Journal:  Gastroenterology       Date:  1972-06       Impact factor: 22.682

8.  A cerebrospinal fluid transfer model for hepatic and uremic encephalopathy.

Authors:  R W Brennan; F Plum
Journal:  Trans Am Neurol Assoc       Date:  1971

9.  Oxygen electrode studies of rat brain respiration in hepatic coma.

Authors:  P T Lascelles
Journal:  Exp Biol Med       Date:  1971       Impact factor: 2.691

10.  Brain distribution spaces of mannitol-3H, inulin-14C, and dextran-14C in the rat.

Authors:  W B Sisson; W H Oldendorf
Journal:  Am J Physiol       Date:  1971-07
View more
  5 in total

1.  Artificial liver support in fulminant hepatic failure.

Authors:  R Williams
Journal:  Bull N Y Acad Med       Date:  1975-04

2.  Physico-chemical aspects of the removal of protein-bound substances by charcoal and other adsorbents of potential value in systems of artificial liver support: Part I--equilibrium properties.

Authors:  E H Dunlop; R D Hughes; R Williams
Journal:  Med Biol Eng Comput       Date:  1978-07       Impact factor: 2.602

Review 3.  Trials and tribulations with artificial liver support.

Authors:  R Williams
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

4.  Fulminant hepatic failure and artificial liver support.

Authors:  A E Gimson; R Ede; S Braude; R D Hughes; P J Langley; R Williams
Journal:  Gastroenterol Jpn       Date:  1982-04

5.  Fulminant liver failure: clinical and experimental study.

Authors:  M Slapak
Journal:  Ann R Coll Surg Engl       Date:  1975-11       Impact factor: 1.891

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.